SNORD37: A Non-Coding RNA Molecule Regulating Gene Expression

Target Name: SNORD37

NCBI ID: G26812

SNORD37

Other Name(s): Small nucleolar RNA, C/D box 37 | RNU37 | small nucleolar RNA, C/D box 37 | U37

SNORD37: A Non-Coding RNA Molecule Regulating Gene Expression

SNORD37, also known as Small Nucleolar RNA (snRNA), is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. It is composed of a core-loop structure and a C/ D box on the 3' end, which give it its unique name.

The discovery and characterization of SNORD37 was made by Dr. Rongtao Xu and his colleagues at the University of California, San Diego, in 2006. They identified a highly conserved RNA molecule that was highly expressed in various tissues and organs, but were unable to determine its function.

Since then, researchers have made significant progress in understanding the function and regulation of SNORD37. Studies have shown that SNORD37 is involved in the regulation of gene expression in various biological processes, including cell growth, differentiation, and apoptosis.

One of the most significant functions of SNORD37 is its role in the regulation of microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation by binding to specific target mRNAs. SNORD37 has been shown to act as a negative regulator of miRNA expression by binding to the miRNA-protein interaction and preventing the binding of miRNA to its target mRNAs.

Another function of SNORD37 is its role in the regulation of gene expression in the cell cycle. Studies have shown that SNORD37 is involved in the regulation of G1/S transition, which is a critical step in the cell cycle that leads to the entry of the cell into the G2 phase.

SNORD37 has also been shown to play a role in the regulation of cellular apoptosis. Apoptosis is a natural and essential process in various organisms, and it is regulated by a complex network of factors, including SNORD37. Studies have shown that SNORD37 can act as a positive regulator of apoptosis by promoting the expression of genes involved in cell survival, and as a negative regulator of apoptosis by promoting the expression of genes involved in cell death.

In addition to its role in gene regulation, SNORD37 has also been shown to play a role in the regulation of RNA stability and translation efficiency. Studies have shown that SNORD37 can act as a positive regulator of RNA stability by binding to the RNA-protein interaction and promoting the translation of RNA into protein, and as a negative regulator of translation efficiency by binding to the ribosome and preventing the initiation of protein translation.

Despite the significant research that has been done on SNORD37, there is still much to be learned about its function and regulation. Further studies are needed to fully understand the mechanisms by which SNORD37 regulates gene expression and to determine its potential as a drug target or biomarker.

In conclusion, SNORD37 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms. Its unique structure and function make it an attractive target for further research and its potential as a drug or biomarker should be further explored.

Protein Name: Small Nucleolar RNA, C/D Box 37

The "SNORD37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets